Bernard Le Foll 2024

Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial

Gabriel Bastien, Anita Abboud, Christina McAnulty, Laurent Elkrief, Omar Ledjiar, Eugenia Socias, Bernard Le Foll, Anees Bahji, Suzanne Brissette, Stéphanie Marsan, DidierJutras-Aswad

Cannabis Use Characteristics Associated with Self-Reported Cognitive Function in a Nationally Representative U.S. sample

Dafna Sara Rubin-Kahana, Kevin Butler, Ahmed Nabeel Hassan, Marcos Sanches, Bernard Le Foll

With increases in cannabis use and potency, there is a need to improve our understanding of the impact of use on cognitive function. Previous research indicates long-term cannabis use may have a negative effect on executive function. Few studies have examined persistence of it in protracted abstinence…

Cannabis use in the COVID-19 pandemic: Changes in different populations and implications for policy in Linking Neuroscience and Behavior in COVID-19

Created by Adam Zaweel, Isaac Kuk, Soyeon Kim, Bernard Le Foll, Christine Wickens.

Participant Fraud in Virtual Qualitative Substance Use Research: Recommendations and Considerations for Detection and Prevention Based on a Case Study

Created by Madison Wright, Justin Matheson, Tara Marie Watson, Beth Sproule, Bernard Le Foll, Bruna Brands

The COVID-19 pandemic has accelerated and amplified the use of virtual research methods. While online research has several advantages, it also provides greater opportunity for individuals

The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial

Created by Anees Bahji, Gabriel Bastien, Paxton Bach, JinCheol Choi, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad & M. Eugenia Socias.

Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated…

Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone

Created by Intishar Kazi, Meghan Chenoweth, Didier Jutras-Aswad, Keith Ahamad, M. Eugenia Socias, Bernard Le Foll, Rachel Tyndale

Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response…

Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials

Created by Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll…

There is currently no standard of care for pharmacological treatment of amphetamine-type stimulant (ATS) use disorder (ATSUD). This systematic review with meta-analysis (PROSPERO CRD42022354492) aimed to pool results from randomized placebo-controlled trials (RCTs) to evaluate efficacy and safety of prescription psychostimulants (PPs) for ATSUD…